Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome
https://www.biospace.com/article/releases/wize-pharma-completes-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogren-s-syndrome/ Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome
Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled
Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled
Wize Pharma Completes Patient Enrollment In Phase 4 Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome
https://www.prnewswire.com/news-releases/wize-pharma-completes-patient-enrollment-in-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome-300990264.html Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome – Topline Results Expected Q2 2020 – Study designed to support approval pathway in the U.S. and other major markets Jan 21, 2020, 09:00 ET HOD HASHARON, Israel, Jan. 21, 2020 […]